semaglutide nejm weight loss Tirzepatide vs for Obesity – NEJM, May 2025 Relevant to endocrinology, internal medicine, cardiology, obesity medicine • Tirzepatide: −20.2% at 72 wks • Semaglutide: −13.7% • Greater waist reduction Phase 3 Trial of Semaglutide

Whether youre wanting to lose a few pounds or need a complete makeover, we are here to help you achieve your goals

Wang, Q., et al

When your target is 25 units (2.5 mg at 10 mg/mL), reading the 25th line on a 0.5 mL syringe is much easier and more accurate than trying to hit the midpoint between 24 and 26 on a 1 mL syringe where lines are spaced closer together

CrossRef Comparison of the effects of empagliflozin and sitagliptin, as add-on to metformin, on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitus Seyed Saman Talebi, Shabnam Rezaie, Minoo Sadat Hajmiri, Maryam Zamanirafe, Akram Ranjbar, Heresh Moridi, Mahtabalsadat Mirjalili, Maryam Mehrpooya Naunyn-Schmiedeberg's Archives of Pharmacology.2024

Wegovy is a prescription weight-loss medication for adults and children 12 and older with obesity or weight-related medical problems

Journal of clinical pharmacology, 55(5), 497504